IKKβ is also implicated in breast cancer bone metastasis [1] and we have recently reported that the indirect inhibition of IKKβ-mediated NFκB activation by the TAK1 (TAK1, TGF-beta-activated kinase 1) inhibitor Celastrol or the NFκB inhibitor Parthenolide reduced the development of osteolysis in a model of breast cancer bone metastasis [1, 20, 22, 27]. This evidence concerns the gene NFKB1 and breast carcinoma.